278 related articles for article (PubMed ID: 22458643)
1. Single and multiple dose intravenous and oral pharmacokinetics of the hedgehog pathway inhibitor vismodegib in healthy female subjects.
Graham RA; Hop CE; Borin MT; Lum BL; Colburn D; Chang I; Shin YG; Malhi V; Low JA; Dresser MJ
Br J Clin Pharmacol; 2012 Nov; 74(5):788-96. PubMed ID: 22458643
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic dose-scheduling study of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors.
Lorusso PM; Jimeno A; Dy G; Adjei A; Berlin J; Leichman L; Low JA; Colburn D; Chang I; Cheeti S; Jin JY; Graham RA
Clin Cancer Res; 2011 Sep; 17(17):5774-82. PubMed ID: 21753154
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors: the role of alpha-1-acid glycoprotein binding.
Graham RA; Lum BL; Cheeti S; Jin JY; Jorga K; Von Hoff DD; Rudin CM; Reddy JC; Low JA; Lorusso PM
Clin Cancer Res; 2011 Apr; 17(8):2512-20. PubMed ID: 21300760
[TBL] [Abstract][Full Text] [Related]
4. A Physiologically Based Pharmacokinetic Model of Vismodegib: Deconvoluting the Impact of Saturable Plasma Protein Binding, pH-Dependent Solubility and Nonsink Permeation.
Dolton MJ; Chiang PC; Ma F; Jin JY; Chen Y
AAPS J; 2020 Sep; 22(5):117. PubMed ID: 32875428
[TBL] [Abstract][Full Text] [Related]
5. A single dose mass balance study of the Hedgehog pathway inhibitor vismodegib (GDC-0449) in humans using accelerator mass spectrometry.
Graham RA; Lum BL; Morrison G; Chang I; Jorga K; Dean B; Shin YG; Yue Q; Mulder T; Malhi V; Xie M; Low JA; Hop CE
Drug Metab Dispos; 2011 Aug; 39(8):1460-7. PubMed ID: 21602311
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and safety of vismodegib in patients with advanced solid malignancies and hepatic impairment.
Abou-Alfa GK; Lewis LD; LoRusso P; Maitland M; Chandra P; Cheeti S; Colburn D; Williams S; Simmons B; Graham RA
Cancer Chemother Pharmacol; 2017 Jul; 80(1):29-36. PubMed ID: 28523596
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic-pharmacodynamic analysis of vismodegib in preclinical models of mutational and ligand-dependent Hedgehog pathway activation.
Wong H; Alicke B; West KA; Pacheco P; La H; Januario T; Yauch RL; de Sauvage FJ; Gould SE
Clin Cancer Res; 2011 Jul; 17(14):4682-92. PubMed ID: 21610148
[TBL] [Abstract][Full Text] [Related]
8. Daily dosing of vismodegib to steady state does not prolong the QTc interval in healthy volunteers.
Graham RA; Chang I; Jin JY; Wang B; Dufek MB; Ayache JA; Ezzet F; Zerivitz K; Low JA; Dresser MJ
J Cardiovasc Pharmacol; 2013 Jan; 61(1):83-9. PubMed ID: 23107871
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of food effect on pharmacokinetics of vismodegib in advanced solid tumor patients.
Sharma MR; Karrison TG; Kell B; Wu K; Turcich M; Geary D; Kang SP; Takebe N; Graham RA; Maitland ML; Schilsky RL; Ratain MJ; Cohen EE
Clin Cancer Res; 2013 Jun; 19(11):3059-67. PubMed ID: 23553850
[TBL] [Abstract][Full Text] [Related]
10. A clinical drug-drug interaction study to evaluate the effect of a proton-pump inhibitor, a combined P-glycoprotein/cytochrome 450 enzyme (CYP)3A4 inhibitor, and a CYP2C9 inhibitor on the pharmacokinetics of vismodegib.
Malhi V; Colburn D; Williams SJ; Hop CE; Dresser MJ; Chandra P; Graham RA
Cancer Chemother Pharmacol; 2016 Jul; 78(1):41-9. PubMed ID: 27154174
[TBL] [Abstract][Full Text] [Related]
11. Co-administration of vismodegib with rosiglitazone or combined oral contraceptive in patients with locally advanced or metastatic solid tumors: a pharmacokinetic assessment of drug-drug interaction potential.
LoRusso PM; Piha-Paul SA; Mita M; Colevas AD; Malhi V; Colburn D; Yin M; Low JA; Graham RA
Cancer Chemother Pharmacol; 2013 Jan; 71(1):193-202. PubMed ID: 23064958
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and pharmacodynamics of single rising intravenous doses (0.5 mg-10 mg) and determination of absolute bioavailability of the dipeptidyl peptidase-4 inhibitor linagliptin (BI 1356) in healthy male subjects.
Retlich S; Duval V; Ring A; Staab A; Hüttner S; Jungnik A; Jaehde U; Dugi KA; Graefe-Mody U
Clin Pharmacokinet; 2010 Dec; 49(12):829-40. PubMed ID: 21053992
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety.
Guo F; Letrent SP; Munster PN; Britten CD; Gelmon K; Tolcher AW; Sharma A
Cancer Chemother Pharmacol; 2008 Jun; 62(1):97-109. PubMed ID: 17805538
[TBL] [Abstract][Full Text] [Related]
14. Plasma pharmacokinetics and bioavailability of 1-(2-chloroethyl)-3-sarcosinamide-1-nitrosourea after intravenous and oral administration to mice and dogs.
Supko JG; Garcia-Carbonero R; Puchalski TA; Malspeis L
Cancer Chemother Pharmacol; 2001 Sep; 48(3):202-8. PubMed ID: 11592341
[TBL] [Abstract][Full Text] [Related]
15. A phase I ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjects.
Abbas R; Hug BA; Leister C; Gaaloul ME; Chalon S; Sonnichsen D
Cancer Chemother Pharmacol; 2012 Jan; 69(1):221-7. PubMed ID: 21691746
[TBL] [Abstract][Full Text] [Related]
16. A novel double-tracer technique to characterize absorption, distribution, metabolism and excretion (ADME) of [14C]tofogliflozin after oral administration and concomitant intravenous microdose administration of [13C]tofogliflozin in humans.
Schwab D; Portron A; Backholer Z; Lausecker B; Kawashima K
Clin Pharmacokinet; 2013 Jun; 52(6):463-73. PubMed ID: 23494983
[TBL] [Abstract][Full Text] [Related]
17. Effects of Mild to Severe Hepatic Impairment on the Pharmacokinetics of Sonidegib: A Multicenter, Open-Label, Parallel-Group Study.
Horsmans Y; Zhou J; Liudmila M; Golor G; Shibolet O; Quinlan M; Emotte C; Boss H; Castro H; Sellami D; Preston RA
Clin Pharmacokinet; 2018 Mar; 57(3):345-354. PubMed ID: 28577129
[TBL] [Abstract][Full Text] [Related]
18. Topical delivery of vismodegib using ablative fractional laser and micro-emulsion formulation in vitro.
Olesen UH; Clergeaud G; Lerche CM; Andresen TL; Haedersdal M
Lasers Surg Med; 2019 Jan; 51(1):79-87. PubMed ID: 30152536
[TBL] [Abstract][Full Text] [Related]
19. Determination of unbound vismodegib (GDC-0449) concentration in human plasma using rapid equilibrium dialysis followed by solid phase extraction and high-performance liquid chromatography coupled to mass spectrometry.
Deng Y; Wong H; Graham RA; Liu W; Shen HS; Shi Y; Wang L; Meng M; Malhi V; Ding X; Dean B
J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Jul; 879(22):2119-26. PubMed ID: 21704573
[TBL] [Abstract][Full Text] [Related]
20. Physiologically Based Pharmacokinetic Models Can Be Used to Predict the Unique Nonlinear Absorption Profiles of Vismodegib.
Lin L; Wright MR; Hop CECA; Wong H
Drug Metab Dispos; 2022 Sep; 50(9):1170-1181. PubMed ID: 35779865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
